)
Solventum (SOLV) investor relations material
Solventum Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 sales were $1.949B, down 7.0% reported and 2.8% organically; the $125M ERP-related advance-order reversal created a ~630 bps organic-growth headwind. Organic growth excluding ERP timing was +3.5%.
Results exceeded expectations; adjusted EPS was $1.45 and FY26 adjusted EPS guidance rose to $7.20–$7.30.
ERP cutovers are complete and more than 90% of transition service agreements have been exited; separation-cost reductions are expected to strengthen Q4 free cash flow.
Transformation priorities remain separation, profitable-growth repositioning, and portfolio optimization.
HIS separation options are under review, with the aim of maximizing shareholder value and supporting long-term growth.
Financial highlights
Q3 net sales were $1.949B; GAAP net loss was $12M, or $(0.07) per diluted share, versus net income of $1.266B and EPS of $7.22 a year earlier, which included a $1.518B sale gain.
Adjusted diluted EPS was $1.45, down 3.6% YoY; adjusted operating income was $387M and adjusted operating margin was 19.9%, down 70 bps.
Gross profit was $1.062B versus $1.135B; adjusted gross margin was 57.1%, up 130 bps YoY, while reported gross margin was 54.5% versus 54.2%.
Cash from operations was $177M and free cash flow was $97M in Q3; 9M cash from operations was $215M and free cash flow was $(32)M.
Normalized organic growth was ~4% excluding ERP timing and 90 bps of SKU-rationalization headwinds; Acera growth would have added ~50 bps to total growth.
Outlook and guidance
FY26 organic sales growth is expected toward the high end of 2.5%–3.0%; excluding ~100 bps of SKU exits, growth is expected toward the high end of 3.5%–4.0%.
FY26 adjusted EPS guidance increased to $7.20–$7.30 from $7.10–$7.20; the new range includes $0.48 from the Q2 tariff refund.
FY26 operating margin is expected toward the high end of 22.2%–22.7%, including a 120 bps benefit from the IEEPA tariff refund; excluding the refund, guidance implies 100 bps YoY expansion.
FY26 free cash flow guidance remains $200M–$300M, with the large majority expected in Q4; underlying FCF is tracking to ~ $1B excluding separation and portfolio costs.
FY26 effective tax rate guidance is 19.5%–20.5%; FX is expected to benefit net sales by ~100 bps, while IEEPA refunds are expected to offset FY26 tariff costs.
- HIS separation supports medtech focus, with growth and margin expansion driven by innovation and efficiencies.SOLV
Wells Fargo 21st Annual Healthcare Conference - Q2 organic sales up 9.5%, adjusted EPS up 50.9%, and full-year guidance raised.SOLV
Q2 2026 - Transformation advances with growth drivers, margin focus, and M&A plans post-divestiture.SOLV
Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Transformation drives innovation, margin expansion, and growth, supported by strong Q1 results.SOLV
Jefferies Global Healthcare Conference 2026 - Directors elected, executive pay approved, and auditors ratified with strong shareholder support.SOLV
AGM 2026 - Transformation ahead of plan, with growth, innovation, and M&A readiness accelerating.SOLV
Stifel 2025 Healthcare Conference - Q3 2025 net income surged on a $4B divestiture, with raised guidance and new cost initiatives.SOLV
Q3 2025 - Raised 2024 guidance as Q2 organic sales grew 1.3% and adjusted EPS reached $1.56.SOLV
Q2 2024 - Targets 4-5% organic sales growth, 23-25% margins, and 10% EPS CAGR by 2028.SOLV
Investor Day 2025
Next Solventum earnings date
Next Solventum earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)